Pfizer Inc. (NYSE:PFE) Stock Holdings Raised by Keystone Financial Planning Inc.

Keystone Financial Planning Inc. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 3.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 214,402 shares of the biopharmaceutical company’s stock after purchasing an additional 6,951 shares during the period. Pfizer makes up approximately 3.7% of Keystone Financial Planning Inc.’s holdings, making the stock its 5th largest holding. Keystone Financial Planning Inc.’s holdings in Pfizer were worth $8,400,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Assenagon Asset Management S.A. increased its holdings in Pfizer by 999.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 82,455 shares of the biopharmaceutical company’s stock valued at $3,231,000 after purchasing an additional 74,955 shares during the period. Halsey Associates Inc. CT increased its holdings in Pfizer by 73.8% during the 3rd quarter. Halsey Associates Inc. CT now owns 44,316 shares of the biopharmaceutical company’s stock valued at $1,592,000 after purchasing an additional 18,822 shares during the period. Arcadia Investment Management Corp MI increased its holdings in Pfizer by 5.0% during the 4th quarter. Arcadia Investment Management Corp MI now owns 20,854 shares of the biopharmaceutical company’s stock valued at $817,000 after purchasing an additional 1,000 shares during the period. Regal Investment Advisors LLC increased its holdings in Pfizer by 46.2% during the 4th quarter. Regal Investment Advisors LLC now owns 165,649 shares of the biopharmaceutical company’s stock valued at $6,490,000 after purchasing an additional 52,337 shares during the period. Finally, TIAA FSB increased its holdings in Pfizer by 5.9% during the 4th quarter. TIAA FSB now owns 713,494 shares of the biopharmaceutical company’s stock valued at $27,954,000 after purchasing an additional 39,583 shares during the period. Institutional investors and hedge funds own 70.16% of the company’s stock.

In related news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were purchased at an average cost of $37.15 per share, with a total value of $37,150.00. Following the transaction, the director now directly owns 4,000 shares in the company, valued at approximately $148,600. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.09% of the company’s stock.

Several analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price objective on shares of Pfizer in a research report on Wednesday, January 29th. Mizuho assumed coverage on Pfizer in a research report on Wednesday, February 5th. They set a “buy” rating and a $42.00 price objective on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a research report on Tuesday, January 28th. Credit Suisse Group reaffirmed a “hold” rating and set a $41.30 price objective on shares of Pfizer in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada assumed coverage on Pfizer in a research report on Monday, January 6th. They set an “outperform” rating and a $46.00 price objective on the stock. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $41.72.

Shares of PFE opened at $36.93 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average price is $39.03 and its 200-day moving average price is $37.57. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $44.56. The stock has a market cap of $209.25 billion, a P/E ratio of 12.87, a P/E/G ratio of 3.09 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 28th. The biopharmaceutical company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.02). Pfizer had a return on equity of 27.23% and a net margin of 31.44%. The company had revenue of $12.69 billion during the quarter, compared to the consensus estimate of $12.73 billion. During the same period in the prior year, the firm earned $0.64 earnings per share. The business’s revenue for the quarter was down 9.2% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.76 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be given a $0.38 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.12%. The ex-dividend date is Thursday, January 30th. Pfizer’s payout ratio is currently 51.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is the S&P/ASX 200 Index?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.